Drreddys Laboratories | RDY - Current Liabilities


Drreddys Laboratories reported INR1.76B in Current Liabilities for its fiscal quarter ending in December of 2025.





Current Liabilities Change Date
ANI Pharmaceuticals USD 270.56M 33.72M Sep/2025
Aurora Cannabis CAD 124.12M 32.76M Sep/2025
Bayer EUR 28.96B 825M Sep/2025
Canopy Growth CAD 81.1M 17.56M Sep/2025
Cipla INR 62.97B 8.13B Sep/2025
Corcept Therapeutics USD 172.26M 27.6M Sep/2025
Drreddys Laboratories INR 1.76B 62.5M Dec/2025
GlaxoSmithKline GBP 21.33B 956M Sep/2025
Hikma Pharmaceutical USD 2.06B 78M Jun/2025
Lonza CHF 3.58B 970M Dec/2024
Novartis USD 32B 286M Sep/2025
Pacira USD 107.08M 206.09M Sep/2025
Prestige Brands USD 134.6M 24.94M Sep/2025
Richter Gedeon HUF 182.16B 6.92B Sep/2025
Sun Pharmaceuticals INR 234.15B 52.21B Sep/2025
Supernus Pharmaceuticals USD 330.63M 44.27M Sep/2025
Teva Pharmaceutical Industries USD 13.46B 1.96B Dec/2025